AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
vinpocetine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| vinca alkaloids | 2828 | 42971-09-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
whole issue of Arzneim Forsch (23 articles) discuss this drug; Arzneim Forsch 26(10a);1976; RN given refers to parent cpd with unspecified isomeric designation
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 15 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 33 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 2.08 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 6.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 4.83 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK1,PDK4,PDPK1,PIK3CA,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 50 | |||
| kinase-selectivity-class | AXL,BRAF,GRK2 | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Tension | 109.82 | 50.47 | 20 | 738 | 3662 | 90624027 |
| Disturbance in attention | 63.17 | 50.47 | 21 | 737 | 47088 | 90580601 |
| Cognitive disorder | 62.54 | 50.47 | 23 | 735 | 69384 | 90558305 |
| Psychomotor retardation | 62.32 | 50.47 | 13 | 745 | 4776 | 90622913 |
| Flat affect | 62.19 | 50.47 | 11 | 747 | 1700 | 90625989 |
| Bradykinesia | 57.81 | 50.47 | 13 | 745 | 6775 | 90620914 |
| Illusion | 51.79 | 50.47 | 9 | 749 | 1255 | 90626434 |
| Autism spectrum disorder | 51.58 | 50.47 | 9 | 749 | 1284 | 90626405 |
| Anhedonia | 51.07 | 50.47 | 13 | 745 | 11418 | 90616271 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Tension | 102.94 | 40.19 | 20 | 924 | 5058 | 110583297 |
| Flat affect | 57.76 | 40.19 | 11 | 933 | 2494 | 110585861 |
| Disturbance in attention | 57.05 | 40.19 | 21 | 923 | 61974 | 110526381 |
| Cognitive disorder | 56.84 | 40.19 | 23 | 921 | 87488 | 110500867 |
| Psychomotor retardation | 55.73 | 40.19 | 13 | 931 | 7779 | 110580576 |
| Bradykinesia | 51.53 | 40.19 | 13 | 931 | 10775 | 110577580 |
| Autism spectrum disorder | 47.70 | 40.19 | 9 | 935 | 1939 | 110586416 |
| Illusion | 47.44 | 40.19 | 9 | 935 | 1998 | 110586357 |
| Overweight | 47.37 | 40.19 | 11 | 933 | 6453 | 110581902 |
| Anhedonia | 46.92 | 40.19 | 13 | 931 | 15415 | 110572940 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N06BX18 | NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Other psychostimulants and nootropics |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D010726 | Phosphodiesterase Inhibitors |
| MeSH PA | D014665 | Vasodilator Agents |
| MeSH PA | D018696 | Neuroprotective Agents |
| MeSH PA | D018697 | Nootropic Agents |
| MeSH PA | D020011 | Protective Agents |
| CHEBI has role | CHEBI:176497 | geroprotector |
Related Drugs by ATC class:
N06BX Other psychostimulants and nootropics 19 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Dementia | indication | 52448006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.03 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 7.41 | CHEMBL | |||||
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Enzyme | IC50 | 5.10 | CHEMBL | |||||
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Enzyme | INHIBITOR | IC50 | 4.30 | IUPHAR | ||||
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Enzyme | IC50 | 5.10 | CHEMBL | |||||
| Phosphodiesterase 1 | Enzyme | IC50 | 4.72 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4024909 | VUID |
| N0000171574 | NUI |
| D01371 | KEGG_DRUG |
| 4024909 | VANDF |
| C0059752 | UMLSCUI |
| CHEBI:32297 | CHEBI |
| T7F | PDB_CHEM_ID |
| CHEMBL71752 | ChEMBL_ID |
| DB12131 | DRUGBANK_ID |
| C013983 | MESH_SUPPLEMENTAL_RECORD_UI |
| 443955 | PUBCHEM_CID |
| 5285 | IUPHAR_LIGAND_ID |
| 4046 | INN_ID |
| 543512OBTC | UNII |
| 24506 | RXNORM |
| 005991 | NDDF |
| 716059001 | SNOMEDCT_US |
Pharmaceutical products:
None